End-of-day quote
Korea S.E.
06:00:00 2024-06-13 pm EDT
5-day change
1st Jan Change
108,900
KRW
+3.03%
+6.97%
+7.82%
Dong-A Socio Holdings Co., Ltd's Equity Buyback announced on October 26, 2022, has expired.
The company expired its plan on January 26, 2023.
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 16
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 20
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
Dong-A ST Sets Sight on European Market with Stelara Biosimilar Expansion
23-08-31
MT
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Dong-A Socio Holdings Co., Ltd's Equity Buyback announced on October 26, 2022, has expired.
23-01-25
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
Dong-A Socio Holdings Co., Ltd. announces an Equity Buyback for 50,301 shares.
22-10-26
CI
Dong-A Socio Holdings Co., Ltd. authorizes a Buyback Plan.
22-10-25
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-16
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-16
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-18
CI
Dong-A Socio Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-15
CI
Dong-A Socio Holdings Co., Ltd. agreed to acquire an additional 29.4% stake in DM Bio, Ltd. from Meiji Seika Pharma Co., Ltd for KRW 42.1 billion.
21-07-22
CI
Dong-A Socio Holdings Co., Ltd.(KOSE:A000640) dropped from KOSPI 200 Index
20-12-10
CI
Tranche Update on Dong-A Socio Holdings Co., Ltd.'s Equity Buyback Plan announced on March 20, 2020.
20-06-22
CI
Tranche Update on Dong-A Socio Holdings Co., Ltd.'s Equity Buyback Plan announced on March 20, 2020.
20-06-22
CI
Dong-A Socio Holdings Co., Ltd.'s Equity Buyback announced on March 20, 2020, has expired with 98,190 shares, representing 1.61% for KRW 8,384.55 million.
20-06-21
CI
Dong-A Socio Holdings Co., Ltd. announces an Equity Buyback for 140,000 shares.
20-03-20
CI
Dong-a Pharmaceutical Co. Ltd. authorizes a Buyback Plan.
20-03-19
CI
Meiji Seika Pharma Co., Ltd. and Dong-A Socio Holdings Co., Ltd. Announces the Initiation of A Phase I Clinical Trial of Dmb-3115
19-12-15
CI
INTAKE Co., Ltd. announced that it has received KRW 3.8 billion in funding from Dong-A Socio Holdings Co., Ltd., SOFTBANK Ventures Korea Inc.
18-02-01
CI
Dong-A Socio Holdings Co. Ltd. cancelled the acquisition of an additional stake in ST Pharm Co. Ltd..
17-08-22
CI
Dong-A Socio Holdings Co. Ltd. cancelled the acquisition of additional 10% stake in ST Pharm Co. Ltd. from Dong-A ST Co., Ltd..
16-12-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dong-A Socio Holdings Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company operates its business through five segments. The Medicine Manufacturing segment is engaged in the manufacture and sale of pharmaceuticals. The main pharmaceuticals include tonic medicines, cold medicines, raw material medicines. The Logistic segment is involved in the freight, courier, car transportation, freight warehousing and leasing business. The Packaging segment is engaged in manufacturing and sale of glass and glass products. The Holding Company segment is engaged in the provision of core companies and management consulting services. The Other segment is engaged in the production and sale of information and communication technology (IT) solutions and agricultural products, as well as real estate development business.
More about the company
Last Close Price
108,900
KRW
Average target price
155,000
KRW
Spread / Average Target
+42.33%
Consensus
1st Jan change
Capi.
+7.82% 492M +50.70% 791B +41.96% 630B -7.15% 350B +18.77% 328B +8.79% 298B +18.02% 246B +1.27% 225B +11.95% 218B +3.68% 160B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1